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Table
Multivariate analysis for overall survival after HCT
Variable Hazard ratio 95% CI P value
Race Ethnicity
White 1.0
Non-white/ Hispanic 1.72 1.03 to 2.87 0.04
Age
<50 1.0
 50 1.60 0.95 to 2.70 0.07
Disease
Lymphoma 1.0
Leukemia/ MDS 1.18 0.58 to 2.42 0.64
Others 1.36 0.42 to 4.41 0.6
Disease risk
Low 1.0
Intermediate 1.24 0.66 to 2.35 0.5
High 2.36 1.39 to 4.00 0.001
Donor
Related 1.0
Unrelated 1.45 0.94 to 2.22 0.08
Conditioning
Reduced intensity 1.0
Myeloablative 1.39 0.85 to 2.3 0.19
Karnofsky performance score
100 1.0
<100 2.92 1.82 to 4.69 < .001
HCT-CI score 1.08 0.97 to 1.19 0.13
CMV status
D-/R- 1.0
Others 1.5 0.85 to 2.64 0.16
Employment status
Employed 1.0
Unemployed 1.03 0.63 to 1.69 0.9
Retired 1.44 0.84 to 2.48 0.18
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underscores the need for better understanding of the factors
responsible for differential outcomes and continued efforts
to eliminate disparities in access and outcomes of HCT.
371
Outcome of Second Transplants in Pediatric Patients with
Hematological Malignancies After a Hematopoietic Stem
Cell Transplant (HSCT) From a Different Donor.
Assessment of Chimerism by Real -Time PCR to
Determine the Risk of Relapse
Sana Khan 1, Marie Olszewski 2, Morris Kletzel 3. 1 Lurie
Children's Hospital, Chicago, IL; 2 Lurie Children's Hospital,
Chicago; 3 Northwestern University Feinberg School of
Medicine, Chicago, IL
A retrospective analysis of 13 patients (9males, 4 females)
aged 1-16 (median, 9) years were transplanted at Lurie
Children's between 2002 to 2011 (AML n¼ 2, ALL n¼11).
Donor sources for the 1st HSCT were 8 match related sibling
(MRS) and 5 unrelated (2/5 cord blood) and for the 2nd HSCT
were 5 MRS and 8 unrelated. Two conditioning regimens; A:
fractionated TBI 1200cGy in 150cGy fractions from day -7 to
-4, Etoposide 1000 mg/m2 from day -3 and Cyclophospha-
mide 60 mg/Kg day -3 to day -1, 1st HSCT (n¼7) and 2nd HSCT
(n¼6), B: Fludarabine 30 mg/m2/day from day -10 to -6,
Busulfan (dose based on PK of the test dose to achieve an AUC
4000microM-min/day) day -5, -4 and ATG (rabbit ATG) 2mg/
kg from day -4 to -9, 1st HSCT (n¼3) and 2nd HSCT (n¼10).
GVHD prophylaxis was regimen speciﬁc for regimen A (CSA/
Tacro, short course MTX  ATG) and regimen B (CSA/Tacro,
MMF ECP). Chimerism was evaluated by real-time PCR
(Applied Biosystems 7500) using AlleleSEQR (Cellera),
weekly after the second week, full donor chimerism (FDC)
was deﬁned as >98%  1%. Median time from diagnosis to1st HSCT was 202 days. The median time from the 1st to the
2nd HSCT was 531 days. ANC > 500 /mL was achieved at
a median of 15 (10-39) days in the 1st, compared to 18.5 (10-
25) days after the 2nd (P ¼ .7). Un-sustained platelet count
>20.0/ mL was attained at amedian of 16.5 (1-54) days and 19
(0-54) days at 1st and 2nd (P ¼ .8), respectively. FDC was
achieved at a median of 34.5 (12-63) days in 13/13 after the
1st and a median of 44 (22-108) days in 10/13 after the 2nd.
The median follow-up after the 2nd HSCT was 1259 (35-
3508) days. The Kaplan- Meier estimates of survival at 3 and
5 years were 69.2% and 43.3%, respectively (median follow up
of 1735 days). Seven patients (1 with partial chimerism, 6
with FDC) are alive after the 2nd HSCT, free of disease with
a median follow up of 1562 (range 915-3508) days. Six
patients have expired, three of cGVHD complications in
remission (3 with FDC) and three patients expired from
progressive leukemia (2 with partial chimerism). Patients
who relapse after the 1st myeloablative HSCT can be
successfully treated with a 2nd HSCT from a different donor.
Patients who did not achieve a FDC after the 2nd transplant
were at a higher risk of relapse. One patient with partial
chimerism has remained in CR after developing graft failure
after the 2nd HSCT, but achieving FDC from the ﬁrst donor.
Patients who developed cGVHD after the 2nd transplant with
a FDC did not relapse but died of cGVHD complications in
remission. All but one of the surviving patients has cGVHD.
Chimerism analysis is the index for which the risk of relapse
is determined. Larger number of patients will be needed to
conﬁrm these preliminary observations.372
Outcome of Allogeneic Hematopoietic Stem Cell
Transplantation for Severe Aplastic Anemia Using
Fludarabine, Reduced-Dose Cyclophosphamide, and ATG
Sumiko Kohashi, Takehiko Mori, Jun Kato, Akiko Yamane,
Shinichiro Okamoto. Division of Hematology, Keio University
School of Medicine, Tokyo, Japan
Background: Although allogeneic hematopoietic stem cell
transplantation (HSCT) has beenwidely performed for severe
aplastic anemia (SAA), the standard conditioning regimen
has yet to be established. Recently, the outcomes of a variety
of reduced-intensity conditioning regimens using ﬂudar-
abine have been reported.
Aims: We have retrospectively evaluated the safety and
efﬁcacy of allogeneic HSCT for SAA using ﬂudarabine,
reduced-dose cyclophosphamide, and ATG.
Patients & Methods: Six patients (median age 30 (range:
22-61)) with SAA who underwent allogeneic bone marrow
transplantation from an HLA-identical sibling (n¼3) or an
HLA-matched unrelated donor (n¼3) were evaluated.
Conditioning included ﬂudarabine (120 mg/m2), cyclop-
hosphamide (100 mg/kg), and ATG (Thymoglobulin;
3.75 mg/kg). In addition, 2 Gy of TBI (with ovarian shielding
for young female patients) was delivered for heavily trans-
fused patients or HSCT from an unrelated donor. For the
prophylaxis of graft-versus-host disease (GVHD), cyclo-
sporine A or tacrolimus with short-term methotrexate was
given.
Results: The transplant procedure was generally well-toler-
ated and there were no life-threatening complications. All
patients achieved neutrophil and platelet engraftment and
became transfusion independent. Full donor chimerism was
conﬁrmed on whole bone marrow cells at day 28 after
transplantation. Only one patient developed acute GVHD
(grade II) and none developed chronic GVHD. With a median
follow-up period of 15.9 months (range: 11.6-22.4 months),
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patient experienced progressive pancytopenia, requiring red
blood cell transfusion, in spite of the full donor chiemrism
both in the bone marrow and peripheral blood T cells.
Chimerism analysis of the peripheral blood T cells was
analyzed later than 6 months post-transplant, showing
mixed chimerism in 3 patients with stable hematopoiesis.
The recovery of menstruationwas observed in all 4 evaluable
young female patients at 3, 7, 8, and 9 months after trans-
plantation, respectively.
Conclusion: These results suggest that this regimen could be
a safe and effective conditioning regimen of allogeneic HSCT
for SAA both from sibling and unrelated donor. However,
long-term follow-up is needed to further evaluate the
dynamics of T-cell chimerism and the incidence of late-onset
graft failure.373
The Outcome of Allogeneic Hematopoietic Stem Cell
Transplantation Following Liver Transplantation in
Children with Immunodeﬁciencies
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Background: Case reports of allogeneic hematopoietic stem
cell transplantation (HSCT) following liver transplantation in
children with immunodeﬁciencies have been published in
the past and have described correction of the underlying
disease.
The objective of this study is to report the clinical
outcomes of a series of pediatric recipients of allogeneic
hematopoietic stem cell transplantation following previous
liver transplantation.
Method: Retrospective analysis of 8 patients who underwent
HSCT following previous liver transplantation between
2003-2012 at a single institution.
Results: Seven patients (4 males and 3 females) underwent
orthotopic whole liver transplantation for fulminant or
chronic liver disease of unknown etiology; 1 male patient
received segmental liver transplantation for alpha-1 anti-
trypsin deﬁciency. Six of 8 patients underwent reduced
intensity conditioning while 2/8 received myeloablative
conditioning prior to allogeneic hematopoietic stem cell
transplantation. Seven patients received unrelated donor
HSCT and 1 patient had a matched sibling donor. Seven
patients were later diagnosed with hemophagocytic lym-
phohistiocytosis (HLH), 5/7 with negative genetic studies for
known genes of HLH, including one with Epstein Barr Virus-
induced HLH, 1 patient with X-linked inhibitor of apoptosis
deﬁciency-induced HLH, 1 patient with combined immune
deﬁciency. All patients engrafted. Two patients died before
day 100, 1 patient has been lost of follow up more than 2
years after HSCT, 4 patients are alive for +3 years with good
life quality, and one patient has recently been transplanted.
Two patients with mild or no transaminitis still receive lowdose of immune suppressive drugs for liver transplant as
directed by their surgeons.
Conclusion: HLHmay present with fulminant or cryptogenic
liver failure requiring correction with orthotopic liver
transplantation prior bone marrow transplantation. Ortho-
topic liver transplantation followed by unrelated donor HSCT
using reduced intensity conditioning can lead to relevant
immune reconstitution with stably improved quality of life
and resolution of HLH.374
Survival Advantage of the Addition of Cell Therapy to
Chemotherapy in Adult Patients with Relapsed AML After
Allogeneic Hematopoietic Cell Transplantation
Ghada M. Kunter 1, Janelle Perkins 2, Taiga Nishihori 3,
Frederick Locke 3, Teresa Field 3, Joseph Pidala 4, Lia Perez 3,
Mohamed Kharfan-Dabaja 3, Claudio Anasetti 3,
Hugo Fernandez 3. 1 Blood and Marrow Transplantation, H. Lee
Mofﬁtt Cancer Center and Research Institute, University of
South Florida, Tampa, FL; 2 BMT, Mofﬁtt Cancer Center, Tampa,
FL; 3 Blood and Marrow Transplantation, H. Lee Mofﬁtt Cancer
Center, Tampa, FL; 4 Hematology/Oncology, Mofﬁtt Cancer
Center, Tampa, FL
Background: There is no standard of care for patients (pts)
with relapsed acute myelogenous leukemia (AML) after
allogeneic hematopoietic cell transplantation (allo HCT).
Outcome is dismal with 2-year overall survival (OS) of< 10%.
Rapid immunosuppression taper to induce graft-versus-
leukemia effect, cell therapy (CT)  chemotherapy, or che-
motherapy(ChT) alone have all been attempted, however,
there is paucity of comparative analysis examining the
outcomes of these strategies.
Methods: To evaluate the efﬁcacy of different approaches,
we conducted a single-institution retrospective analysis
comparing the efﬁcacy of different therapeutic options in
these pts. We assessed the impact of CT versus ChT on their
response and outcomes using uni- and multivariate analysis.
Results: We report the outcomes of 85 adult AML pts;
median age was 50 (range: 19-69) years relapsed post allo
HCT. Median time from transplant to relapse was 4.3 (range,
0.6-45) months (mo). Twenty eight (32%) pts received ChT
with either hypomethylating agents (HMA) or other ChT; 21
(24%) pts received CT, including donor lymphocyte infusion
(DLI) or CD34+ stem cells  ChT; 36 (42%) pts received
supportive care only. The median post HCT follow up of
surviving pts was 9 (range: 2-85) mo. Complete remission
(CR) rate for all pts who received any therapywas 40% (62% of
CTgroup compared to 22% receiving ChT alone (P¼ .002)). CT
produced higher CR rate compared to ChT alone (P ¼ .007).
The median time to relapse after achieving a second CR post
therapy for all pts was 13mowith 14% , 40% and 70% relapsed
by 6, 12 and 24 months respectively. Median OS after relapse
for all pts was 3.7 mo with the best outcome noted in the CT
group at 10.2 mo compared to 3.6 mo for those received ChT
alone. Univariate analysis showed that receiving either CT or
ChT compared to no therapy improved OS (P < .0001);
however there was no difference between CT and ChT (P ¼
.06). Multivariate analysis showed that the pre-HCT cytoge-
netics, CIBMTR risk score, comorbidity index and donor type
had no impact on the CR rate or outcomes. However, CT was
the only signiﬁcant covariate over ChT (P ¼ .0071).
Conclusions: These data suggest that pts who are able to
receive CT in addition to ChT have the best chance of
achieving CR. Future approaches should focus on prospec-
tively combining these modalities to improve OS in AML pts
relapsing post allo HCT.
